 AstraZeneca PLC LSE:AZN said five new drugs had taken on blockbuster status last year generating over US1bn in revenues each as delivered a strong financial performance, boosted by the US39bn takeover of Alexion Pharmaceuticals NASDAQ:ALXN. Total revenues for 2021 were US37.4mln, up 41, while core earnings rose 32 to US5.29 per share. 